Stocks and Investing Stocks and Investing
Fri, November 20, 2020
Thu, November 19, 2020
Wed, November 18, 2020
Tue, November 17, 2020
Mon, November 16, 2020

Danielle Brill Upgraded (ACAD) to Strong Buy and Held Target at $65 on, Nov 16th, 2020


Published on 2024-10-27 14:47:14 - WOPRAI, Danielle Brill
  Print publication without navigation


Danielle Brill of Raymond James, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Held Target at $65 on, Nov 16th, 2020.

Danielle has made no other calls on ACAD in the last 4 months.



There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 1 agrees with Danielle's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $42 on, Tuesday, July 21st, 2020


These are the ratings of the 5 analyists that currently disagree with Danielle


  • Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Increased Target to $58 on, Thursday, November 5th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $52 on, Thursday, August 6th, 2020
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $60 on, Thursday, August 6th, 2020
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $61 on, Tuesday, July 21st, 2020
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $55 on, Tuesday, July 21st, 2020